Literature DB >> 10896671

Nerve growth factor (NGF) loop 4 dimeric mimetics activate ERK and AKT and promote NGF-like neurotrophic effects.

Y Xie1, M A Tisi, T T Yeo, F M Longo.   

Abstract

Previous work indicating that nerve growth factor (NGF) protein loops 2 and 4 interact with TrkA receptors raise the possibility that small molecule mimetics corresponding to TrkA-interacting domains that have NGF agonist activity can be developed. We applied our previously developed strategy of dimeric peptidomimetics to address the hypothesis that loop 4 small molecule dimeric mimetics would activate TrkA-related signal transduction and mimic NGF neurotrophic effects in a structure-specific manner. A loop 4 cyclized peptide dimer demonstrated NGF-like neurotrophic activity, whereas peptides with scrambled sequence, added or substituted residues, or cyclized in monomeric form were inactive. Activity was blocked by the TrkA inhibitors K252a and AG879 but not by NGF p75 receptor blocking antibody. Dimeric, but not monomeric, peptides partially blocked NGF activity. This profile was consistent with that of a NGF partial agonist. ERK and AKT phosphorylation was stimulated only by biologically active peptides and was blocked by K252a. The ERK inhibitor U0126 blocked the neurite- but not the survival-promoting activity of both NGF and active peptide. These studies support the proof of concept that small molecule NGF loop 4 mimetics can activate NGF signaling pathways and can mimic death-preventing and neurite-promoting effects of NGF. This finding will guide the rational design of NGF single-domain mimetics and contribute to elucidating NGF signal transduction mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896671     DOI: 10.1074/jbc.M005071200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Role of the conformational versatility of the neurotrophin N-terminal regions in their recognition by Trk receptors.

Authors:  Francesca Stanzione; Luciana Esposito; Antonella Paladino; Carlo Pedone; Giancarlo Morelli; Luigi Vitagliano
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Alzheimer's therapeutics: neurotrophin domain small molecule mimetics.

Authors:  Stephen M Massa; Youmei Xie; Frank M Longo
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

3.  Novel low-molecular-weight mimetics of the nerve growth factor.

Authors:  T A Gudasheva; T A Antipova; S B Seredenin
Journal:  Dokl Biochem Biophys       Date:  2010-10-20       Impact factor: 0.788

4.  Molecular simulation of the binding of nerve growth factor peptide mimics to the receptor tyrosine kinase A.

Authors:  Marco Berrera; Antonino Cattaneo; Paolo Carloni
Journal:  Biophys J       Date:  2006-06-23       Impact factor: 4.033

Review 5.  Neuroprotective strategies in Alzheimer's disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  NeuroRx       Date:  2004-01

6.  P2Y2 receptor activates nerve growth factor/TrkA signaling to enhance neuronal differentiation.

Authors:  David B Arthur; Katerina Akassoglou; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 7.  Functions and the related signaling pathways of the neurotrophic factor neuritin.

Authors:  Jin-Jing Yao; Qian-Ru Zhao; Jun-Mei Lu; Yan-Ai Mei
Journal:  Acta Pharmacol Sin       Date:  2018-03-29       Impact factor: 6.150

8.  Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists.

Authors:  Jing Liu; Fouad Brahimi; H Uri Saragovi; Kevin Burgess
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

9.  Tyrphostin ErbB2 Inhibitors AG825 and AG879 Have Non-specific Suppressive Effects on gp130/ STAT3 Signaling.

Authors:  Hyun Kyoung Lee; In Ae Seo; Sang Hwa Lee; Su-Young Seo; Kyung Sup Kim; Hwan Tae Park
Journal:  Korean J Physiol Pharmacol       Date:  2008-10-31       Impact factor: 2.016

10.  Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice.

Authors:  Maxime Cazorla; Anne Jouvenceau; Christiane Rose; Jean-Philippe Guilloux; Catherine Pilon; Alex Dranovsky; Joël Prémont
Journal:  PLoS One       Date:  2010-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.